Century Therapeutics (IPSC)

Executive Summary

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company pioneering the development of allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs). Its platform enables the scalable production of engineered immune cells, including natural killer (NK) and T cells, designed to enhance persistence, potency, and specificity while mitigating host rejection. The company's pipeline targets hematologic malignancies and solid tumors, with lead programs in relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, and extends into autoimmune diseases. By leveraging precision gene editing and a renewable iPSC master cell bank, Century aims to overcome key limitations of autologous cell therapies, such as manufacturing complexity and patient accessibility. Century is currently conducting Phase 1 clinical trials for its lead candidates: CNTY-101, an iPSC-derived NK cell therapy targeting CD19 for B-cell non-Hodgkin lymphoma, and CNTY-102, an iPSC-derived CAR-T therapy targeting BCMA for multiple myeloma. Early data have shown encouraging safety and preliminary efficacy, with updated results expected in the coming quarters. The company also has preclinical programs in autoimmune indications, with an IND filing anticipated this year. While still in early stages, Century's platform has attracted strategic collaborations, providing non-dilutive funding and validation. Key upcoming milestones include clinical data readouts at medical conferences and the advancement of autoimmune programs into the clinic, which could serve as significant value inflections.

Upcoming Catalysts (preview)

• Q4 2026Updated Phase 1 data for CNTY-101 or CNTY-102 at a major medical conference75% success
• Q3 2026IND filing for autoimmune program (e.g., CNTY-201 in lupus)60% success
• TBDAnnouncement of new strategic partnership or collaboration30% success